Financial Data and Key Metrics Changes - The company ended Q1 with $138 million on the balance sheet, projecting cash to last until February 2028, allowing for continued clinical development of its programs [57] - The company expects meaningful readouts from the combination of its two lead programs and the new program in the clinic within the cash runway timeframe [58] Business Line Data and Key Metrics Changes - The company has three candidates in development, focusing on synthetic lethality in oncogene amplified tumors, with two lead programs being a selective Check1 inhibitor and a selective RNR inhibitor [10][15] - The company is exploring a combination therapy approach to enhance efficacy while managing safety concerns, with plans to dose both compounds weekly instead of daily [17][23] Market Data and Key Metrics Changes - The company operates in a niche market addressing oncogene amplification, which affects approximately 25% of all cancer patients, representing a significant unmet medical need [2][60] - The competitive landscape is evolving, with major pharmaceutical companies beginning to explore the e cDNA space, indicating growing interest in this area [52][54] Company Strategy and Development Direction - The company aims to leverage its proprietary SpyGlass platform to identify novel targets and develop therapies specifically for cancers driven by e cDNA [6][9] - The strategic focus includes expanding its pipeline with additional novel targets while ensuring efficient use of capital to sustain operations and development [66] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenging biotech market environment but emphasizes the importance of demonstrating clinical efficacy to gain investor confidence [60][64] - The company is optimistic about its innovative approach and the potential for significant advancements in cancer treatment, positioning itself as a leader in the e cDNA space [64][66] Other Important Information - The company has developed a proprietary diagnostic tool called Echo to detect e cDNA, which integrates with standard multi-gene panels, enhancing its clinical studies [49][50] - The company is in the IND enabling phase for its new program targeting a novel kinesin oral degrader, with plans to initiate patient dosing in the first half of next year [45][46] Q&A Session Summary Question: What is the company's cash position and runway? - The company ended Q1 with $138 million, projecting cash to last until February 2028, allowing for continued clinical development of its programs [57] Question: What are the next steps for the combination therapy? - The company is awaiting FDA feedback on the combination therapy and plans to initiate patient dosing in the next couple of months [39][40] Question: How does the company view competition in the e cDNA space? - The company recognizes growing interest from major pharma companies in the e cDNA area but believes it remains a leader due to its focused research and proprietary platform [52][54] Question: What is the company's strategy for future target identification? - The company plans to continue identifying novel targets and drugs while being mindful of macroeconomic conditions affecting capital availability [66]